ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
REGENXBIO Inc

REGENXBIO Inc (RGNX)

10.95
-0.26
( -2.32% )
Updated: 15:40:10

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.508.0010.709.209.350.000.00 %015-
5.004.008.500.006.250.000.00 %00-
7.501.506.000.003.750.000.00 %00-
10.001.051.951.271.50-0.38-23.03 %6315:09:34
12.500.150.650.450.400.000.00 %0332-
15.000.150.750.200.450.000.00 %0341-
17.500.100.500.150.300.000.00 %020-
20.000.230.750.230.490.000.00 %036-
22.500.260.750.260.5050.000.00 %069-
25.000.420.750.420.5850.000.00 %012-
30.000.190.750.190.470.000.00 %08-
35.000.550.750.550.650.000.00 %01-
40.001.000.751.000.8750.000.00 %021-

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.750.000.000.000.00 %00-
5.000.000.750.000.000.000.00 %00-
7.500.000.250.000.000.000.00 %00-
10.000.100.500.250.300.000.00 %018-
12.501.502.451.201.9750.000.00 %0271-
15.003.604.702.994.150.000.00 %0275-
17.506.107.305.906.700.000.00 %035-
20.008.6010.307.659.450.000.00 %054-
22.509.0013.505.5011.250.000.00 %03-
25.0011.5016.0013.4013.750.000.00 %08-
30.0016.5021.000.0018.750.000.00 %00-
35.0021.5026.000.0023.750.000.00 %00-
40.0026.5031.400.0028.950.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RZLVRezolve AI Ltd
$ 7.52
(52.85%)
2.93M
RNAZTransCode Therapeutics Inc
$ 0.6288
(50.83%)
9.53M
ATGLAlpha Technology Group Limited
$ 2.175
(50.76%)
3.16M
INVZWInnoviz Technologies Ltd
$ 0.18
(45.69%)
11.02k
OCTOEightco Holdings Inc
$ 3.58
(43.78%)
99.28M
VTNRVertex Energy Inc
$ 0.1523
(-57.81%)
46.68M
CMCTCreative Media and Community Trust Corporation
$ 0.7031
(-55.07%)
3.34M
SFIXStitch Fix Inc
$ 2.305
(-38.53%)
20.07M
SHOTWSafety Shot Inc
$ 0.22
(-31.25%)
11.25k
BNZIBanzai International Inc
$ 5.725
(-30.52%)
2.67M
NVDANVIDIA Corporation
$ 123.33
(2.04%)
243.47M
MLGOMicroAlgo Inc
$ 0.2724
(25.99%)
133.53M
CEROCERo Therapeutics Holdings Inc
$ 0.09965
(6.35%)
119.52M
SQQQProShares UltraPro Short QQQ
$ 7.4999
(-1.96%)
112.41M
OCTOEightco Holdings Inc
$ 3.572
(43.45%)
99.28M

RGNX Discussion

View Posts
crudeoil24 crudeoil24 3 years ago
36M share trading float.

RGNX
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
AbbVie And REGENXBIO Announce Eye Care Collaboration; AbbVie To Pay REGENXBIO $370M Upfront Payment And Up To $1.38B In milestones
6:31 am ET September 13, 2021 (Benzinga) Print
AbbVie (NYSE:ABBV) and REGENXBIO Inc. (NASDAQ:RGNX) today announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials utilizing in-office suprachoroidal delivery.

Under the collaboration, REGENXBIO will be responsible for completion of the ongoing trials of RGX-314. AbbVie and REGENXBIO will collaborate and share costs on additional trials of RGX-314, including the planned second pivotal trial evaluating subretinal delivery for the treatment of wet AMD and future trials. AbbVie will lead the clinical development and commercialization of RGX-314 globally. REGENXBIO shall participate in U.S. commercialization efforts as provided under a mutually agreed upon commercialization plan.

"We are committed to finding solutions for patients living with difficult-to-treat retinal diseases and to helping preserve and protect our patients from visual impairment and devastating vision loss," said Tom Hudson, MD, senior vice president, R&D, chief scientific officer, AbbVie. "In collaboration with REGENXBIO, we aim to make a remarkable impact for the millions of patients suffering from vision loss associated with retinal diseases."

"AbbVie is a strong, complementary partner for REGENXBIO. We expect to leverage AbbVie's global developmental and commercial infrastructure within eye care with our expertise in AAV gene therapy clinical development and deep in-house knowledge of manufacturing and production to continue the development of RGX-314," said Kenneth T. Mills, president and chief executive officer of REGENXBIO.

Under the terms of the agreement, AbbVie will pay REGENXBIO a $370 million upfront payment with the potential for REGENXBIO to receive up to $1.38 billion in additional development, regulatory and commercial milestones. REGENXBIO and AbbVie will share equally in profits from net sales of RGX-314 in the U.S. AbbVie will pay REGENXBIO tiered royalties on net sales of RGX-314 outside the U.S. In addition, REGENXBIO will lead the manufacturing of RGX-314 for clinical development and U.S. commercial supply, and AbbVie will lead manufacturing of RGX-314 for commercial supply outside the U.S.
πŸ‘οΈ0
StockLearner2011 StockLearner2011 5 years ago
https://www.google.com/amp/s/www.nasdaq.com/article/4-gene-therapy-players-likely-to-become-buyout-targets-in-2019-cm1125990/amp
πŸ‘οΈ0
StockLearner2011 StockLearner2011 5 years ago
I believe the buyout is in a distance future. JUNO has the same trading behavior before buyout was announced!
πŸ‘οΈ0
Zmill Zmill 5 years ago
is there an argument for a BO? https://msmoneymoves.com/2019/05/28/could-this-biotech-stock-get-bought-for-5-5-billion-either-way-im-buying-it/
πŸ‘οΈ0
BlackEyePatch BlackEyePatch 5 years ago
Strong buy @ 50!!!!
πŸ‘οΈ0
stocktrademan stocktrademan 6 years ago
RGNX buy 66.90























normal chart




log chart



πŸ‘οΈ0
StockLearner2011 StockLearner2011 6 years ago
Hope no more form 4s for insider selling
πŸ‘οΈ0
StockLearner2011 StockLearner2011 6 years ago
Let’s see how tomorrow will be
πŸ‘οΈ0
StockLearner2011 StockLearner2011 6 years ago
Why insiders sold at $34 and $37 while the target price is $90? Anybody has any clue?
πŸ‘οΈ0
StockLearner2011 StockLearner2011 6 years ago
$45 soon! Yummy
πŸ‘οΈ0
stocktrademan stocktrademan 8 years ago
RGNX bullish 14.39



normal chart


log chart

πŸ‘οΈ0
protagonist12 protagonist12 8 years ago
Agreed, would like to to see the stock come down to single digits before buying though. Still only in preclinical trials and burning a ton of cash.
πŸ‘οΈ0
floWteiuQ floWteiuQ 8 years ago
Interesting play here for the long term. Very good technology with a lot of prospects for them and licensing.
πŸ‘οΈ0
protagonist12 protagonist12 9 years ago
RGNX no bid support, too early still, listed VC...
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock